Organogenesis Q2 2026 net loss widens to $96.3 million; net revenue drops 58% to $42.8 million vs Q2 2025 - ORGO News | RalliesOrganogenesis Q2 2026 net loss widens to $96.3 million; net revenue drops 58% to $42.8 million vs Q2 2025
O
ORGO• Outlook
- The company cut its 2026 net revenue outlook to $179 million-$215 million, implying a 62%-68% decline.
- CEO Gary S. Gillheeney cited slower-than-expected recovery despite measured improvement.
Second-quarter results
- Organogenesis posted a GAAP net loss of $96.3 million, or $0.77 per share, for Q2 2026.
- Net revenue fell 58% year over year to $42.8 million, led by a 61% slide in Advanced Wound Care to $36.1 million.
- Gross profit dropped to $19.1 million from 45% of net product revenue, down 28 percentage points year over year.
- GAAP operating loss widened to $51 million; adjusted EBITDA loss widened to $34.4 million.
•
